Eligibility for PI (Performance Improvement) CME Credit

Yale CME is offering Performance Improvement activities to support healthcare providers in making appropriate changes to their practice.

PI CME credit can be earned through a structured process in which physicians engage in a self-assessment process, document evidence-based performance measures, participate in an educational intervention, apply performance improvement measures prospectively over a useful interval, and complete a post-intervention self-assessment to measure change in clinical practice behavior. Up to 20 AMA PRA Category 1 Credits™ can be earned through this process.

Diabetes 2009 has been designated to be PI CME credit-eligible.

After participating in this activity, attendees will review a random sampling of 25 records of their patients with diabetes, age 18-75, to determine the percentage of patients at target glucose, blood pressure, and lipid management and those receiving periodic diabetes-related health screening (foot and dilated retinal exams). After initial data collection, the attendee is encouraged to implement a quality improvement program (such as in–chart reminders, flow sheets, engaging support staff triggering of clinical alerts, etc.) Data collection should then be repeated after full implementation of the program on the same number of patient records. Comparisons between the ‘before’ and ‘after’ pictures will allow a critical look at one important aspect concerning the quality of care delivered by the attendee in his/her practice/clinic setting.

If you wish to participate in this particular activity, you must select one or more of the PI Learning Objectives and complete 5 or more Data Collection forms for each Learning Objective selected.

You must complete the Data Collection Form and Evaluation specific to the 3rd Annual Yale Musculoskeletal Review Course for the Primary Care Provider.

Learning Objectives
At the conclusion of this program, the participant should be able to:

• Explain the pathogenesis of Type 2 diabetes, especially the coexisting roles of insulin resistance and insulin secretion.
• Describe the evolving cellular mechanisms associated with beta cell failure, the progression of diabetes, and its complications.
• Implement strategies for the early diagnosis and treatment of diabetes.
• Recognize the clinical manifestations of the macrovascular and microvascular complications of diabetes and describe appropriate therapeutic interventions.
• Recognize the interrelationship between insulin resistance, hyperglycemia, and atherosclerosis in patients with Type 2 diabetes.
• Compare the mechanisms of actions of the various pharmacologic agents for the treatment of diabetes, their risks and benefits, and their proper role in the management of this disease.
• Identify evolving and emerging management strategies for diabetes (e.g., combination therapies, new insulin delivery systems, new glucose monitoring techniques, novel drugs.)
• Describe the approach to managing dyslipidemia, hypertension, and cardiovascular risk factors in patients with diabetes.
• Identify unique management issues among special sub-populations of patients with diabetes.
• Discuss the impact of diabetes on the healthcare system.

For more information on how to complete the PI process, please visit Performance Improvement.